The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions

Daniela Pende, Alessandro Poggi, Marco Scudeletti, Domenico Criscuolo, Francesco Indiveri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

MDL-899 is new phthalazine derivative which has been developed as a substitute for hydralazine, which has several undesirable effects, in the treatment of hypertension. The effects of MDL-899 on human lymphocyte functions are analyzed. This drug inhibited in a dose-related fashion the blastogenesis of lymphocytes upon PHA and Con A activation and down-regulated the activation of allogeneic mixed lymphocyte reactions (MLR). On the contrary the drug enhanced the activation of autologous MLR of non T/T type. This effect was five times higher on cells which carried the HLA DR 4 phenotype. The above reported observations suggest that MDL-899, as well as hydralazine, affects the in vitro responsiveness of human lymphocytes mostly in subjects with HLA-DR 4 phenotype. Whether the impact of MDL-899 on immune function gives rise to a lupus like syndrome is not known. For this reason further studies are warranted to assess its long-term in vivo effects.

Original languageEnglish
Pages (from-to)385-390
Number of pages6
JournalInternational Journal of Immunopharmacology
Volume8
Issue number4
DOIs
Publication statusPublished - 1986

Fingerprint

Lymphocytes
Hydralazine
Mixed Lymphocyte Culture Test
HLA-DR Antigens
Phenotype
Lymphocyte Activation
Hypertension
mopidralazine
phthalazine
Pharmaceutical Preparations
Therapeutics
In Vitro Techniques
Metabolic Activation

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions. / Pende, Daniela; Poggi, Alessandro; Scudeletti, Marco; Criscuolo, Domenico; Indiveri, Francesco.

In: International Journal of Immunopharmacology, Vol. 8, No. 4, 1986, p. 385-390.

Research output: Contribution to journalArticle

Pende, Daniela ; Poggi, Alessandro ; Scudeletti, Marco ; Criscuolo, Domenico ; Indiveri, Francesco. / The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions. In: International Journal of Immunopharmacology. 1986 ; Vol. 8, No. 4. pp. 385-390.
@article{5d537b026a2f41289944c732a7873bd4,
title = "The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions",
abstract = "MDL-899 is new phthalazine derivative which has been developed as a substitute for hydralazine, which has several undesirable effects, in the treatment of hypertension. The effects of MDL-899 on human lymphocyte functions are analyzed. This drug inhibited in a dose-related fashion the blastogenesis of lymphocytes upon PHA and Con A activation and down-regulated the activation of allogeneic mixed lymphocyte reactions (MLR). On the contrary the drug enhanced the activation of autologous MLR of non T/T type. This effect was five times higher on cells which carried the HLA DR 4 phenotype. The above reported observations suggest that MDL-899, as well as hydralazine, affects the in vitro responsiveness of human lymphocytes mostly in subjects with HLA-DR 4 phenotype. Whether the impact of MDL-899 on immune function gives rise to a lupus like syndrome is not known. For this reason further studies are warranted to assess its long-term in vivo effects.",
author = "Daniela Pende and Alessandro Poggi and Marco Scudeletti and Domenico Criscuolo and Francesco Indiveri",
year = "1986",
doi = "10.1016/0192-0561(86)90122-0",
language = "English",
volume = "8",
pages = "385--390",
journal = "International Journal of Immunopharmacology",
issn = "0192-0561",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - The effects of a new phthalazine derivative (MDL 899) on human lymphocyte functions

AU - Pende, Daniela

AU - Poggi, Alessandro

AU - Scudeletti, Marco

AU - Criscuolo, Domenico

AU - Indiveri, Francesco

PY - 1986

Y1 - 1986

N2 - MDL-899 is new phthalazine derivative which has been developed as a substitute for hydralazine, which has several undesirable effects, in the treatment of hypertension. The effects of MDL-899 on human lymphocyte functions are analyzed. This drug inhibited in a dose-related fashion the blastogenesis of lymphocytes upon PHA and Con A activation and down-regulated the activation of allogeneic mixed lymphocyte reactions (MLR). On the contrary the drug enhanced the activation of autologous MLR of non T/T type. This effect was five times higher on cells which carried the HLA DR 4 phenotype. The above reported observations suggest that MDL-899, as well as hydralazine, affects the in vitro responsiveness of human lymphocytes mostly in subjects with HLA-DR 4 phenotype. Whether the impact of MDL-899 on immune function gives rise to a lupus like syndrome is not known. For this reason further studies are warranted to assess its long-term in vivo effects.

AB - MDL-899 is new phthalazine derivative which has been developed as a substitute for hydralazine, which has several undesirable effects, in the treatment of hypertension. The effects of MDL-899 on human lymphocyte functions are analyzed. This drug inhibited in a dose-related fashion the blastogenesis of lymphocytes upon PHA and Con A activation and down-regulated the activation of allogeneic mixed lymphocyte reactions (MLR). On the contrary the drug enhanced the activation of autologous MLR of non T/T type. This effect was five times higher on cells which carried the HLA DR 4 phenotype. The above reported observations suggest that MDL-899, as well as hydralazine, affects the in vitro responsiveness of human lymphocytes mostly in subjects with HLA-DR 4 phenotype. Whether the impact of MDL-899 on immune function gives rise to a lupus like syndrome is not known. For this reason further studies are warranted to assess its long-term in vivo effects.

UR - http://www.scopus.com/inward/record.url?scp=0022503959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022503959&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(86)90122-0

DO - 10.1016/0192-0561(86)90122-0

M3 - Article

C2 - 2943687

AN - SCOPUS:0022503959

VL - 8

SP - 385

EP - 390

JO - International Journal of Immunopharmacology

JF - International Journal of Immunopharmacology

SN - 0192-0561

IS - 4

ER -